KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Adrian C Newland, Jeffrey A Allen, Yoshitaka Miyakawa, Peter Ulrichts, Luc Truyen, Jana Podhorna, Rene Kerstens, Sophie Steeland, Jon Beauchamp, Jeffrey T Guptill, James F Howard

Expert Rev Clin Immunol 21(5) 627-638

PMID40296516
PMCID-
DOI10.1080/1744666X.2025.2497840
发表日期2025-04-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Efgartigimod is approved in multiple regions for the treatment of gMG, ITP, and CIDP, and is being evaluated in multiple IgG-mediated autoimmune diseases. Here, we report the long-term safety profiles of efgartigimod IV and PH20 SC across different dosing regimens and diseases where efgartigimod has received regulatory approval. RESEARCH DESIGN AND METHODS: Efgartigimod safety was assessed across dosing regimens and administration routes in Phase 2, placebo-controlled Phase 3, and OLE studies in participants with gMG, ITP, and CIDP. Analyses were performed on all participants who received ≥ 1 dose or partial dose of efgartigimod or placebo. Data from efgartigimod-treated participants were pooled per disease. Event rates were calculated as events per PYFU. RESULTS: Pooled data included 715 participants representing > 850 PYFU. In efgartigimod-treated participants, most TEAEs were mild-to-moderate in severity, with consistently low event rates for TEAE-related treatment discontinuation (range: 0.05-0.47). Severe and serious infection rates were comparable between placebo- and efgartigimod-treated participants. Rates of TEAEs, severe and serious infections, and treatment discontinuation did not increase with prolonged efgartigimod exposure. Efgartigimod did not reduce albumin or increase LDL cholesterol levels. CONCLUSIONS: Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。